Another potential roadblock is the appearance of what are called projection artifacts that are similar to shadows cast on the deeper vasculature by vessels located near the surface.
Fortunately, the data collected to date suggest that vascular damage related to glaucoma tends to affect the more superficial (inner) layers of the retina, which makes current OCTA technology usable regardless of projection artifacts.
At the same time, continuing software improvements are reducing the impact of projection artifacts, extending the useful range of OCTA into deep layers of the retina.
“OCTA is not quite ready for routine clinical use in glaucoma, but that time is coming,” Dr. Chopra said.
“Researchers at UCLA and other centers continue to advance the practical application of this technology to glaucoma. We might expect to see the first clinically useful applications of OCTA in glaucoma begin to emerge within the next six to 12 months.”